Study finds mosaicism in Down syndrome reduces Alzheimer’s risk, providing new insights into genetic influences on cognitive decline and dementia progression.
FDA approves Sandoz’s natalizumab biosimilar, likely putting a damper on Biogen’s Tysabri sales
On the back of Sandoz’s FDA approval for the first-ever natalizumab biosimilar, branded as Tyruko, Biogen now has a formidable multiple sclerosis market competitor for
August 26, 2023